Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS study of zoledronic acid in high-risk non-metastatic prostate cancer
NL-OMON23035Active, not recruiting
- Sponsor
- European Association of Urology
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of zoledronic acid in prostate cancer (PCa) (2 arms), sponsored by European Association of Urology. Primary endpoint: Proportion of patients developing bone metastases. Started Jan 2004; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON23035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23035.